Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

ON DEMAND - Quality Oversight of Pharmacovigilance Processes

Session Chair(s)

David  Fryrear, MS

David Fryrear, MS

Executive Vice President and Head of Quality Assurance

Astellas, United States

Oversight is essential to assure that pharmacovigilance processes remain in a state of control, responsibilities are being performed as assigned, and that the quality management system supporting pharmacovigilance is effective. Effective oversight is an ongoing monitoring activity that looks at processes end-to-end, verifying that they are designed well and executed in a consistent and systematic way. Feedback loops from oversight activities are essential to drive continuous improvement. Oversight approaches must advance to keep up with the ever-increasing complexity of pharmacovigilance activities as well as the new opportunities presented by technology. Quality assurance auditing, the classic oversight tool, is evolving to leverage technology to be both more effective and efficient. Continuous evaluation of process performance, end-to-end through communication of safety information via labeling, is critical to assuring the correct linkages and that the process is always completed as expected. Assessing the external landscape and using the intelligence obtained provides and important way to check that the pharmacovigilance system is complete and stanards are aligned with current expectations. This session will cover how different approaches can contribute to a robust oversight model across the continuum of pharmacovigilance activities.

Learning Objective : Recognize innovations in quality oversight through remote audit techniques; Describe how regulatory intelligence can be leveraged as a strategic compliance advantage; Identify how the Company Core Data Sheet (CCDS) can be manage to assure that safety information is consistent and complete globally.

Speaker(s)

Marina  Suvakov, MS

Robust Regulatory Intelligence: A First Step Towards Compliance

Marina Suvakov, MS

Otsuka, United Kingdom

Director, Compliance and Business Management, Global Pharmacovigilance (GPV)

Gaurav  Shah, PharmD, PhD

Quality Oversight of Pharmacovigilance Processes by Technology Driven Remote Audits

Gaurav Shah, PharmD, PhD

APCER Life Sciences, India

Vice President & Head of Information Technology

Luca  Cariolato, PhD, MSc

CCDS or Local Labeling, a Chicken-and-Egg Situation? The Dilemma of the Product Reference Information Across the Consistency

Luca Cariolato, PhD, MSc

UBC, United States

Senior Safety Scientist

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.